Twist incorporates Molcure AI into antibody discovery efforts

By The Science Advisory Board staff writers

July 26, 2021 -- Twist Bioscience announced that it has used Molcure's artificial intelligence (AI) technology to generate new cancer antibodies.

Molcure's AI platform is based on evolutionary molecular engineering, next-generation sequencing, and laboratory automation technologies. Together, the companies generated potent, binding antibodies to an undisclosed oncology target for Twist's internal pipeline of antibody candidates.

Twist and Molcure attribute the success in part to a technology agreement between the two firms under which they are working to develop new antibody targets, they said.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.